Solara Active Pharma Sciences announced that an income tax demand of 1.62 billion rupees (161.92 crore rupees) for Assessment Year 2019-20 has been reduced to nil following a rectification order under Section 154. The order removes all contingent liability without penalties, strengthening the API maker's financial profile.
CHENNAI / THANE — Active pharmaceutical ingredients (API) manufacturer Solara Active Pharma Sciences Limited announced that a previously issued income tax demand amounting to 1.62 billion rupees (161.92 crore rupees / $19.4 million) has been reduced to nil following a successful rectification order passed by tax authorities. In regulatory filings submitted to Indian stock exchanges, the company confirmed that the Deputy Commissioner of Income Tax, Central Circle-3, Thane, issued the revised rectification order under Section 154 of the Income Tax Act, 1961, effectively erasing the disputed tax addition. The development is critical today as it eliminates a major contingent tax overhang from the drugmaker's balance sheet, strengthening financial clarity and investor confidence amid ongoing capital restructuring and debt reduction programs.
Background of the Disputed Income Tax Assessment
The tax dispute originated from an assessment order previously passed under Section 143(3) read with Section 147 of the Income Tax Act, 1961, pertaining to Assessment Year 2019-20 (AY 2019-20).
Under the original demand notice issued under Section 156 of the Income Tax Act, tax assessing officers had disallowed specific business expenditures and deductions claimed by Solara Active Pharma Sciences in its annual corporate income tax return. The resulting adjustment added 161.92 crore rupees to the company’s taxable income, creating an aggregate tax liability of approximately 1.62 billion rupees alongside associated interest provisions.
Upon receiving the initial notice, Solara Active Pharma Sciences maintained that the expense disallowances were factually incorrect and grounded in apparent clerical and reconciliatory errors on the tax portal. Rather than entering prolonged multi-stage appellate litigation, the company filed a statutory rectification petition under Section 154, submitting complete transaction vouchers, audited ledger reconciliations, and statutory compliance certificates to substantiate the claimed deductions.
Rectification Order Details and Full Liability Relief
Following a comprehensive re-examination of the documentary evidence and audit submissions, the Deputy Commissioner of Income Tax accepted the company’s clarifications. The tax department subsequently issued a revised rectification order modifying the original assessment:
Original Tax Demand: 1,619.2 million rupees (161.92 crore rupees).
Disputed Assessment Year: Assessment Year 2019-20.
Revised Liability Post-Rectification: Nil (Zero rupees).
Statutory Provision: Section 154 of the Income Tax Act, 1961.
Penalties Imposed: Nil.
The order confirms that the disallowed business expenses have been fully allowed, extinguishing all associated claims for unpaid corporate taxes, statutory interest, and ancillary penal charges.
Balance Sheet Deleveraging and Operational Context
The complete erasure of the 1.62 billion rupee tax liability arrives at a pivotal juncture for Solara Active Pharma Sciences, which has been executing an aggressive balance sheet deleveraging strategy.
The company successfully raised equity capital through consecutive rights issue tranches, bringing down total corporate debt from nearly 999 crore rupees to approximately 500–530 crore rupees. This capital restructuring significantly improved its gearing ratio from 1.9 times to below 1.0 time, lifting debt protection metrics and interest coverage. Eliminating the 161.92 crore rupee contingent liability ensures that internal cash generation and rights issue proceeds remain dedicated to core operational capacity expansion and high-margin API product development.
Solara Active Pharma Sciences operates large-scale US FDA-compliant manufacturing facilities across Tamil Nadu, Karnataka, and Maharashtra, supplying active ingredients for essential therapeutic segments, including anti-inflammatory, cardiovascular, central nervous system, and anti-infective formulations.
Impact on Investors, Creditors, and Pharmaceutical Markets
The resolution of the tax demand delivers positive clarity across corporate and financial markets:
Elimination of Balance Sheet Provisions: Public shareholders and institutional investors are relieved of potential provisioning risks or cash escrow requirements that could have constrained working capital.
Improved Credit Profile: Rating agencies evaluate contingent liabilities closely; removing an unprovisioned tax claim exceeding 1.6 billion rupees reinforces corporate creditworthiness and debt-servicing stability.
Regulatory Precedent: The swift resolution via statutory rectification underscores the efficacy of formal administrative mechanisms in resolving complex industrial tax discrepancies without multi-year legal friction.
Official Sources Section
This report is based on regulatory disclosures submitted by Solara Active Pharma Sciences under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, alongside official assessment records issued by:
Quote Section
"According to company officials in regulatory filings, Solara Active Pharma Sciences has received the formal rectification order under Section 154 of the Income Tax Act from the Deputy Commissioner of Income Tax, Thane, completely reducing the proposed income tax demand of 1.62 billion rupees for AY 2019-20 to nil, with no adverse impact on company operations or finances."
Why It Matters
Resolving large tax claims through statutory rectification prevents prolonged litigation that locks up enterprise working capital. For Solara Active Pharma Sciences, the complete elimination of the 1.62 billion rupee demand protects cash reserves, clears corporate governance uncertainties, and supports the company's financial turnaround in the global active pharmaceutical ingredients market.
Key Facts at a Glance
Company: Solara Active Pharma Sciences Limited (BSE: 540653 / NSE: SOLARA).
Original Demand: 1.62 billion rupees (161.92 crore rupees) for Assessment Year 2019-20.
Issuing Authority: Deputy Commissioner of Income Tax, Central Circle-3, Thane.
Current Status: Reduced to Nil following an order under Section 154 of the Income Tax Act.
Financial Impact: Zero liability, zero penalties, and full removal of related contingent overhangs.
Frequently Asked Questions (FAQ)
Why was the 1.62 billion rupee tax demand originally issued against Solara Active Pharma Sciences?
The original notice was issued under Section 143(3) read with Section 147 for Assessment Year 2019-20 due to disallowances of certain business expenditure claims in the company's tax filings.
How was the tax demand reduced to nil?
Solara Active Pharma Sciences submitted a rectification application with reconciliatory documentation under Section 154 of the Income Tax Act, which was accepted by the assessing authority.
Did the company pay any penalty under the revised order?
No. The rectification order completely vacated the addition, resulting in zero payable tax and no penalties.
What does Solara Active Pharma Sciences manufacture?
Solara Active Pharma Sciences is a major Indian manufacturer of active pharmaceutical ingredients (APIs) and advanced intermediates for global pharmaceutical formulations.
Source:
